image0a08.jpg

 
 
 
Exhibit 99.1
 
 
 
 
Earnings Release FY19 Q3
Investor Contacts
Media Contact
 
 
Gerry Gould, VP-Investor Relations
Carla Burigatto, VP-Communications
 
 
(781) 356-9402
(781) 348-7263
 
 
gerry.gould@haemonetics.com
carla.burigatto@haemonetics.com
 
 
 
 
 
 
Olga Vlasova, Sr. Mgr.-Investor Relations
 
 
 
(781) 356-9763
 
 
 
olga.vlasova@haemonetics.com
 
 
 
 
 
Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal 2019 Results; Raises Cash Flow Guidance and Reaffirms Other Fiscal 2019 Guidance

Braintree, MA, February 5, 2019
- Haemonetics Corporation (NYSE: HAE) reported results for its third quarter and year-to-date ("YTD") fiscal 2019, which ended December 29, 2018:    
 
3rd Quarter 2019
YTD 2019
Revenue, increase
$247 million, +5.7%
$718 million, +7.1%
Revenue increase, constant currency
+5.9%
+6.7%
Net income per diluted share
$0.35
$0.64
Adjusted net income per diluted share
$0.63
$1.78
Cash flow from operating activities
$58 million
$139 million
Free cash flow before restructuring & turnaround
$37 million
$58 million

Chris Simon, Haemonetics’ CEO, stated: “Our third quarter performance met our expectations and reinforces that our strategy is working. Our Plasma and Hospital launches are propelling us forward while our Complexity Reduction Initiative is improving profitability and freeing up resources needed for investments. We are confident that our value drivers will continue to strengthen Haemonetics’ growth trajectory.”

GAAP RESULTS

Third quarter fiscal 2019 revenue of $247.4 million was up 5.7% and YTD fiscal 2019 revenue of $718.3 million was up 7.1%, compared with the same periods of fiscal 2018. Business unit revenue and revenue growth rates versus prior fiscal year periods were as follows ($ million):
 
3rd Quarter 2019
YTD 2019
Plasma
$131.8
+16.6%
$373.1
+15.0%
Hospital
$ 48.4
+3.6%
$145.3
+8.1%
Blood Center
$ 67.2
( 9.5%)
$199.9
( 5.5%)

Gross margin was 44.9% in the third quarter of fiscal 2019, down 270 basis points as compared with the same quarter of the prior year, as $4.8 million of accelerated device depreciation was included in the third quarter of the current fiscal year.

1

The following information was filed by Haemonetics Corp (HAE) on Tuesday, February 5, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
×

Membership Level change

You have selected the Free membership level.

Get 7 days of FREE access to our online tools for reading 10-Ks and 10-Qs more efficiently:

  • Bullish, Bearish remarks
  • No advertisements
  • Disclosures
  • Wider reading area
  • Email notifications
  • Stock screener

The price for membership is $0.00 now.

Membership expires after 7 Days.


Account Information Already have an account? Log in here

LEAVE THIS BLANK
Your privacy is important to us - We do not rent or sell your personal information
By creating an account, you are agreeing to our Terms and Privacy Policy

Log in with your credentials

or    

Forgot your details?

Create Account